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Attitudes Toward COVID-19 and COVID-19 Vaccinations Among Athletic Trainers
Abstract
Purpose: Following the beginning of the pandemic brought about by the novel coronavirus which causes
COVID-19, the first COVID-19 vaccination received emergency use authorization in the United States
of America in December of 2020. Current research has shown the authorized COVID-19 vaccines are
safe and effective at preventing severe illness, hospitalizations and death have a good safety profile.
Additionally, the side effects associated with these vaccines are typically mild to moderate while the
protection against hospitalization and severe disease is substantial. (https://www.cdc.gov/coronavirus/
2019-ncov/vaccines/safety/adverse-events.html). At the time of this study, there appears to be a paucity
in the research related to the attitudes toward COVID-19 and COVID-19 vaccines among athletic trainers.
The purpose of this study is to describe the attitudes toward COVID-19 and COVID-19 vaccines among
athletic trainers. Methods: A total of 186 athletic trainers (age= 43 ± 11, years of certified experience =
20 ± 11) opened and completed the survey. Participants were sent an electronic survey via email that
collected demographic information and assessed attitudes toward COVID-19 and COVID-19 vaccines. Data
was downloaded and analyzed using a commercially available statistics package. Results: The majority of
athletic trainers surveyed had received a COVID-19 vaccination at the time of this study (94.1%, n=175).
Most athletic trainers also agreed that the health of their patients was more important than disruption of
their competition season due to COVID-19 (82.3%, n=153). In general, the most common reason for vaccine
hesitancy was the speed with which currently available COVID-19 vaccines were developed. Conclusions:
The findings of this study show the majority of surveyed athletic trainers had received a COVID-19 vaccine.
The primary reason for athletic trainers not receiving a COVID-19 vaccination appeared to be the speed at
which the currently available COVID-19 vaccines were developed. Given the available information on the
new mRNA COVID vaccines, this may indicate a lack of education on the development of the COVID-19
vaccines. As athletic trainers continue to work in day-to-day patient care, it is imperative to determine the
best methods for educating athletic trainers on the potential benefits of COVID-19 vaccinations.
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ABSTRACT
Purpose: Following the beginning of the pandemic brought about by the novel coronavirus which causes COVID-19, the first
COVID-19 vaccination received emergency use authorization in the United States of America in December of 2020. Current
research has shown the authorized COVID-19 vaccines are safe and effective at preventing severe illness, hospitalizations and
death have a good safety profile. Additionally, the side effects associated with these vaccines are typically mild to moderate while
the protection against hospitalization and severe disease is substantial. (https://www.cdc.gov/coronavirus/2019ncov/vaccines/safety/adverse-events.html). At the time of this study, there appears to be a paucity in the research related to the
attitudes toward COVID-19 and COVID-19 vaccines among athletic trainers. The purpose of this study is to describe the attitudes
toward COVID-19 and COVID-19 vaccines among athletic trainers. Methods: A total of 186 athletic trainers (age= 43 ± 11, years
of certified experience = 20 ± 11) opened and completed the survey. Participants were sent an electronic survey via email that
collected demographic information and assessed attitudes toward COVID-19 and COVID-19 vaccines. Data was downloaded and
analyzed using a commercially available statistics package. Results: The majority of athletic trainers surveyed had received a
COVID-19 vaccination at the time of this study (94.1%, n=175). Most athletic trainers also agreed that the health of their patients
was more important than disruption of their competition season due to COVID-19 (82.3%, n=153). In general, the most common
reason for vaccine hesitancy was the speed with which currently available COVID-19 vaccines were developed. Conclusions:
The findings of this study show the majority of surveyed athletic trainers had received a COVID-19 vaccine. The primary reason
for athletic trainers not receiving a COVID-19 vaccination appeared to be the speed at which the currently available COVID-19
vaccines were developed. Given the available information on the new mRNA COVID vaccines, this may indicate a lack of education
on the development of the COVID-19 vaccines. As athletic trainers continue to work in day-to-day patient care, it is imperative to
determine the best methods for educating athletic trainers on the potential benefits of COVID-19 vaccinations.
Keywords: SARS-CoV-2, coronavirus, vaccination, COVID-19
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INTRODUCTION
Coronavirus disease 19 (COVID-19) is a respiratory disease caused by a viral infection with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2).1 COVID-19 was first identified by researchers and healthcare professionals in late 2019 in Wuhan,
China.1 Since its identification, the disease has been shown to be highly infectious.1 Symptoms of COVID-19 may include fever,
dry cough, sore throat, fatigue, loss of smell, loss of taste, muscle and joint pain, shortness of breath, nausea, vomiting, and
diarrhea.1 Patients have developed potentially fatal pneumonia, septic shock, metabolic acidosis, and coagulation dysfunction in
severe cases.2 During the first several months of the COVID-19 pandemic, mitigation efforts centered around testing, contact
tracing, enhanced hygiene, and the use of face masks or face coverings.3-6 Thus, the primary recommendations to mitigate the
spread of COVID-19 had been targeted towards those non-pharmaceutical mitigation efforts.3-6 In December 2020, the mRNA BNT
162b2 (Pfizer) vaccine for COVID-19 received emergency use authorization from the United States Food and Drug Administration
(FDA).7 On August 23, 2021, the FDA granted full approval to the mRNA BNT162b2 COVID-19 vaccine for individuals 16 years of
age and older.8
Extensive research has been done on the mRNA BNT 162b2 vaccine and the 0(Moderna) vaccine. This research has shown that
the mRNA BNT 162b2 and mRNA-1273 vaccines have been found to be very effective at preventing severe COVID-19 illness.9-20
In addition to being effective at preventing severe illness, these vaccines have also been found to be safe as well. Several studies
have reported that the adverse effects experienced with these vaccines are often mild, and the risk of adverse effects as a result
of vaccination is lower than the risk of a serious medical event caused by COVID-19 infection.9,11,16,19,21 A study by Barda et al21
assessed the occurrence of adverse effects in 884,828 people in the United States of America who had been fully vaccinated with
the mRNA BNT 162b2 vaccine. The researchers found that there was no elevated risk associated with most of the severe adverse
outcomes that were examined.21 Although the vaccine was associated with a risk of myocarditis at a rate of one to five events per
100,000, it was noted that this risk was substantially lower than the risk of myocarditis associated with COVID-19 illness.21
One line of reasoning used by some individuals when determining whether or not to receive a COVID-19 vaccination is that natural
immunity may be more potent than vaccine induced immunity.22 In response to this belief, a systematic review was conducted to
determine how the immune response generated from COVID-19 vaccines compared to the immune response created by previous
COVID-19 illness.22 The authors noted that natural immunity was at least as effective as vaccine induced immunity. However, the
authors cautioned that this did not mean individuals should seek out infection to forego vaccination. 22 Rather, they stated in no
uncertain terms that vaccine induced immunity carried far fewer risks than COVID-19 illness without vaccine protection.22
Even though COVID-19 vaccines have been shown to be effective and safe, vaccine hesitancy still exists among some
populations.23,24 This hesitancy has even extended to healthcare professionals such as nurses.23,24 To date, there has been limited
study on the attitudes of athletic trainers toward COVID-19 vaccinations and COVID-19 in general.25,26 Athletic trainers are called
to perform patient-facing care, similar to nurses and other allied healthcare professionals. As such, this places them at an elevated
risk of exposure and infection from COVID-19.27 Athletic trainers are also at a higher risk for mental health concerns such as stress,
anxiety, and depression as a result of providing healthcare during the COVID-19 pandemic.28-30 These issues make athletic trainers
an important population to study as the effects of the COVID-19 pandemic are assessed. Furthermore, healthcare providers play
a crucial role in influencing the uptake of various vaccinations.31-33 This provides even more reason for needing to understand the
feelings and opinions of athletic trainers toward COVID-19 vaccinations. Thus, the purpose of this study was to describe the
attitudes toward COVID-19 vaccination and COVID-19 in general among athletic trainers.
METHODS
Design
This study was conducted using a cross-sectional design with an internet-based survey for data collection. This study was approved
through The University of Texas at Tyler Institutional Review Board.
Respondents
Participants were recruited by emailing head athletic trainers of institutions of higher education and secondary schools using
publicly available staff directories, the recipients were asked to forward the inviting email to any fellow athletic trainers they knew.
Additionally, program directors for athletic training education programs were emailed and asked to forward the study invitation to
their alumni databases and preceptors. A total of 186 athletic trainers (age= 43 ± 11, years of certified experience = 20 ± 11)
opened and completed the survey. Demographic information for participants is presented in Table 1. All participants were informed
of the survey’s purpose and an informed consent question was used to obtain permission to include their data.
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Table 1. Totals and percentages for participant demographic information.
Demographic Factor
Criteria
Sex
Female
Male
Non-Binary
Race
White
Latino(a)
Black or African American
Asian
Other
Highest Degree Earned Professional Bachelors’
Professional Masters’
Post-Professional Masters’ in Athletic Training
Post-Professional Masters’ not in Athletic Training
Academic Doctorate
Clinical Doctorate
Practice Setting
Secondary School
College/University – Clinical
College/University – Split Appointment
College/University – Academic
Emerging Settings
Professional Sports
Clinic/Hospital

2

Responses
103, 55.4%
82, 44.1%
1, 0.5%
167, 89.8%
5, 2.7%
5, 2.7%
4, 2.2%
5, 2.7%
22, 11.8%
46, 24.7%
34, 18.3%
57, 30.6%
18, 9.7%
9, 4.8%
31, 16.7%
108, 58.1%
14, 7.5%
29, 15.6%
2, 1.1%
1, 0.5%
1, 0.5%

Instrumentation
The survey used in this study was based on questions used in previous survey-based studies by the research team.25,26 The survey
began with institutional review board information, the informed consent question, and demographics section. Other questions
gathered information on whether the participants had been previously diagnosed with COVID-19, received a COVID-19
vaccination, and if someone closed to them had been hospitalized or passed away as a result of COVID-19. Further questions
gauged attitudes of participants toward COVID-19 vaccinations, and COVID-19 in general.
The survey consisted of 21 total questions. These questions included: one question obtaining consent to participate in the study,
three fill in the blank and three multiple choice questions regarding demographic information, one multiple choice question about
previous diagnosis of COVID-19, one multiple choice question on receipt of a COVID-19 vaccination, one multiple choice question
regarding whether or not the participant had had someone close to them hospitalized due to COVID-19, one multiple choice
question regarding whether or not the participant had had someone close to them pass away due to COVID-19, and nine multiple
choice questions and one fill in the blank question related to attitudes toward COVID-19 vaccinations and COVID-19 in general.
Procedures
An email was sent to head athletic trainers of institutions of higher education and secondary schools using publicly available staff
directories, the recipients were asked to forward the inviting email to any fellow athletic trainers they knew. Additionally, program
directors for athletic training education programs were emailed and asked to forward the study invitation to their alumni databases
and preceptors. Participants were asked to complete the survey as honestly and completely as possible. The email included an
invitation to participate in a survey, and a link from a web-based survey company (Qualtrics Inc., Provo, UT) in September 2021.
A follow up email was sent two-weeks after the initial invitation attempting to solicit further responses, and the survey was closed
a week after the second email was sent.
Data Analysis
Information from participant responses was downloaded and analyzed using a commercially available statistics package (SPSS
Version 28, IBM, Armonk, NY). A total of 186 athletic trainers consented to participate in the study. All 186 responses were included
in the data analysis. Measures of central tendency (means, standard deviations, frequencies) were calculated where appropriate.
Pearson Correlations were performed to assess relationships between age, experience, and attitudes toward COVID-19
vaccinations, and COVID-19 in general. Independent samples t-tests were performed to assess differences in attitudes between
gender, participants who had or had not had someone close to them hospitalized due to COVID-19, and participants who had or
had not had someone close to them pass away due to COVID-19. A paired samples t-test was performed to assess differences in
responses to questions regarding concern over playing seasons and concern over patient health.
© The Internet Journal of Allied Health Sciences and Practice, 2022
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RESULTS
Receipt of a COVID-19 Vaccination
The majority of participants reported having received a COVID-19 vaccination (94.1%, n=175). A breakdown of vaccination
status is included in Table 2.
Table 2. COVID-19 Vaccination Statuses
Statement
Received mRNA-1273 Vaccination
Received mRNA BNT 162b2 Vaccination
Received JNJ-78436735 (Johnson & Johnson) Vaccination
Unvaccinated

Responses
91, 48.9%
78, 41.9%
6, 3.2%
11, 5.9%

Attitudes Toward COVID-19
When asked about the impact COVID-19 had on those close to them, 40.3% of participants reported having someone close to
them hospitalized due to COVID-19 (n=75). Additionally, 23.1% of participants reported having someone close to them pass away
due to COVID-19 (n=43). The majority of participants agreed that symptoms related to COVID-19 were more severe than influenza
(86%, n=160). Most participants also agreed that COVID-19 was more contagious than influenza (89.2%, n=166). Whether or not
the participant had someone close to them hospitalized or pass away from COVID-19 did not have a significant impact on attitudes
related to the seriousness or contagiousness of COVID-19.
Most athletic trainers also expressed some level of concern related to COVID-19 impacting the competition seasons of their patient
populations (83.3%, n=155). However, the majority of athletic trainers agreed that the health of their patients was more important
than disruption of their patients playing season (82.3%, n=153). When comparing strength of agreement, there was a significant
difference between concern over COVID-19 impacting competition seasons (4.54 ± 1.30) and concern over patient health over
COVID-19 impacting competition seasons (4.84 ± 1.37), p = 0.037.
Attitudes Toward COVID-19 Vaccines
The majority of participants agreed on some level that they felt the current level of FDA authorization for available COVID-19
vaccines was enough for them to be comfortable receiving a vaccination (88.2%, n=164). Most participants also agreed that they
felt more confident in the mRNA BNT 162b2 vaccine after the FDA granted full approval (73.1%, n=136). Table 3 provides a
breakdown of the questions on participants’ attitude toward COVID-19 vaccines.
Table 3. Responses for questions on the attitudes toward COVID-19 vaccines.
Statement
I feel comfortable with the current level of authorization for available COVID-19
vaccines.
I am more confident in the mRNA BNT 162b2 vaccine now that it has received
full FDA approval for individuals over the age of 16.

Most Common Responses (%)
Strongly Agree, 78 (41.9%)
Agree, 55 (29.6%)
Somewhat Agree, 31 (16.7%)
Agree, 63 (33.9%)
Somewhat Agree, 51 (27.4%)
Strongly Agree, 22 (11.8%)

When asked about reasons behind not getting vaccinated, the majority of unvaccinated participants stated they were concerned
about how quickly the available vaccines seemed to be developed. Other comments, which are quoted from participant
responses, regarding reasons for remaining unvaccinated included:
“I am currently breastfeeding my infant and wanted to wait until he either weaned or any of the vaccines gained FDA
approval.”
“I don’t have hardly any risk factors and I’ve already recovered from COVID without any issues.”
“I have had COVID twice and both times I experienced mild flu like symptoms and my immune response was adequate
to fight the virus.”
“Because I believe it is NOT a vaccine. Nothing in the ingredients make it a vaccine.”
“I still have the COVID-19 antibodies from my COVID infection and believe my natural immunity is better than the
vaccine.”
“I do not trust the long-term safety of receiving the vaccine.”
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DISCUSSION
The purpose of this study was to describe the attitudes of athletic trainers toward COVID-19 and COVID-19 vaccines. Additionally,
this study described the receipt of COVID-19 vaccines among this sample.
The majority of participants reported having received a COVID-19 vaccine at the time of the survey (94.1%, n=175). Among the
participants who had not been vaccinated for COVID-19, the most common reasons included concern about how quickly the
vaccines seemed to be developed, and the feeling that previous COVID-19 infection had given them sufficient immunity to severe
illness. The athletic trainers who expressed hesitancy in receiving a COVID-19 vaccine are not an isolated group. Other allied
healthcare professionals, such as nurses, have also expressed reservations regarding receiving a COVID-19 vaccine.23,24 When
hesitancy towards receiving a vaccine is present, educating the involved stakeholders is critical. 34,35
Regarding the concern about how quickly the COVID-19 mRNA vaccines were developed, this may be due to a lack of
understanding of the technology used to develop mRNA vaccines. While the mRNA BNT 162b2 and mRNA-1273 COVID-19
vaccines were developed in under a year, the technology used to do so has been around for significantly longer. 7 In fact, mRNA
vaccines and the technology to develop them have been researched at least as early as 2003.36 Over the past two decades, further
studies have been conducted to develop mRNA vaccines.38-42 Based on this information, the technology used to develop the mRNA
COVID-19 vaccines in actuality took closer to two decades to develop.
When considering the assertion that natural immunity is more potent than vaccine-based immunity, there are factors that warrant
consideration. First, current studies have shown that the immunity obtained through COVID-19 vaccination is comparable to
immunity obtained through COVID-19 infection.22 This suggests natural immunity does have a potentially protective effect against
COVID-19 infection. However, the potential severe adverse effects of the currently available COVID-19 vaccines are generally less
common and less severe than the potential severe adverse effects of COVID-19 infection.22 This underscores the increased risk
of COVID-19 infection relative to COVID-19 vaccination. As such, researchers have emphatically advised against seeking out
SARS-CoV-2 infection in lieu of receiving a COVID-19 vaccine.22
This information suggests potential knowledge gap among some athletic trainers regarding COVID-19 and COVID-19 vaccines.
While this study did not explore the potential for a knowledge gap, such a gap could negatively impact the number of athletic
trainers receiving a COVID-19 vaccination. As allied healthcare professionals tasked with the fundamental responsibility to prevent
injury and illness in their patients, athletic trainers owe it to their patients and their profession to fully examine the scientifically
backed evidence supporting the use of COVID-19 vaccines. By approaching the matter from a more informed perspective, athletic
trainers will be able to make educated decisions regarding their personal plans of care and while counseling patients on healthcare
decisions.
In the current work environment, allied healthcare professionals are experiencing increasing amounts of stress, anxiety, and other
mental health issues.25,28,43 This serves as another reason to attempt to encourage those athletic trainers who are hesitant about
receiving a COVID-19 vaccine to fully educate themselves on the safety and efficacy of said vaccines. Any increase in the number
of vaccinated individuals would positively impact the prevalence of severe illness related to COVID-19.9-22
Limitations
A possible limitation of this study was the relatively low number of participants. While the total number of responses was similar to
other survey-based studies conducted on allied healthcare professionals, an exhaustive and larger scale study would provide a
more complete description of the attitudes of athletic trainers toward COVID-19 and COVID-19 vaccines.44,45 This study provides
a framework for conducting such a study.
Recommendations for Future Research
There is a need for further research into the attitudes, moods, and behaviors of athletic trainers and other allied healthcare
professionals related to the COVID-19 pandemic. A previous study investigated the attitudes and receipt of a COVID-19 vaccination
among athletic trainers and suggested the majority of athletic trainers had or intended to receive a COVID-19 vaccination.26 This
study appeared to support the findings of this previous study. However, there is still a portion of the athletic training community
that must be certain a fully educated decision is being made regarding vaccination against COVID-19. Considering the role of allied
healthcare professionals in providing day-to-day patient care, it is important to continually assess the attitudes and intentions they
hold regarding mitigation strategies during the COVID-19 Pandemic. The high vaccination rate among this cohort of athletic trainers
might serve as a model for their patient population.
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CONCLUSION
In conclusion, the majority of surveyed athletic trainers had received a COVID-19 vaccination at the time of data collection. The
majority of participants also reported valuing their patients’ health more than disrupting a competitive season when related to
COVID-19. The primary reason for athletic trainers not receiving a COVID-19 vaccination appeared to be safety concerns
regarding the speed at which the currently available COVID-19 vaccines were developed. Given the available information on
mRNA vaccines, this may indicate a lack of education on the development of the COVID-19 vaccines. As athletic trainers
continue to work in day-to-day patient care, it is imperative to determine the best methods for educating athletic trainers on the
potential benefits of COVID-19 vaccinations.
REFERENCES
1. Zhong BL, Luo W, Mei LH, Zhang QQ, Liu XG, Li WT, Li Y. Knowledge, attitudes, and practices toward COVID-19
among Chinese residents during the rapid rise period of the COVID-19 outbreak: A quick online cross-sectional survey.
International Journal of Biological Sciences. 2020;16(10):1745-1752.
2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019
novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507-513.
3. Patel R, Babady E, Theel ES, Storch GA, Pinsky BA, George KS, Smith TC, Bertuzzi S. Report from the American
Society for Microbiology COVID-19 International Summit, 23 March 2020: Value of diagnostic testing for SARS-CoV2/COVID-19. American Society for Microbiology. 2020;11(2).
4. Ebrahim SH, Memish ZA. COVID-19 – The role of mass gatherings. Travel Medicine and Infectious Disease. 2020.
5. Zhang R, Li Y, Zhang AL, Wang Y, Molina MJ. Identifying airborne transmission as the dominant route for the spread
of COVID-19. Proceeds of the National Academy of Sciences. 2020.
6. Eikenberry SE, Mancuso M, Iboi E, Phan T, Eikenberry K, Kuang Y, Kostelich E, Gumel AB. To mask or not to mask:
Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic. Infectious Disease
Modeling. 2020;5:293-308.
7. Pfizer-BioNTech COVID-19 Vaccine EUA LOA reissued November 19, 2021. U.S. Food & Drug Administration
website. Updated November 19, 2021. Accessed November 26, 2021. Pfizer-BioNTech COVID-19 Vaccine EUA LOA
reissued November 19 2021 (fda.gov)
8. Comirnaty and Pfizer-BioNTech COVID-19. Vaccine. U.S. Food & Drug Administration website. Updated November,
23, 2021. Accessed November 26, 2021. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine | FDA
9. Al K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, Ding B, Dooley J, Girard B, Hillebrand W, Pajon
R, Miller JM, Leav B, McPhee R. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. The New England
Journal of Medicine. 2021.
10. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ,
Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O’Dell S, Schmidt SD, Corbett KS, Swanson PA,
Padilla M, Neuzil KM, Bennet H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Martinez DR,
Baric R, Buchanan W, Luke CJ, Phadke VK, Rostad CA, Ledgerwood, Graham BS, Beigel JH. Safety and
immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. The New England Journal of Medicine.
2020;383(25):2427-2438.
11. Baden LR, El Shaly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB,
McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H,
Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav
B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.
The New England Journal of Medicine. 2021;384(5):304-416.
12. Barda N, Dagan N, Cohen C, Hernan MA, Lipsitch M, Kohane IS, Reis BY, Balicer RD. Effectiveness of a third dose of
the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study. Lancet.
2021.
13. Dagan N, Barda N, Biron-Shental T, Makov-Assif M, Key C, Kohane IS, Hernan MA, Lipsitch M, Hernandez-Diaz S,
Reis BY, Balicer RD. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nature Medicine.
2021;27:1693-1695.
14. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J, Gillson N, Atti A, Islam J,
Karagiannis I, Munro K, Khawam J, Chand MA, Brown CS, Ramsay M, Lopez-Bernal J, Hopkins S. COVID-19 vaccine
coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN):
A prospective, multicentre, cohort study. Lancet. 2021;397(1725-1735).
15. Jabal KA, Ben-Amram H, Beirtui K, Batheesh Y, Sussan C, Zarka S, Edelstein M. Impact of age, ethnicity, sex and
prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: Realworld evidence from healthcare workers, Israel, December 2020 to January 2021. Eurosurveillance. 2021;26(6).
© The Internet Journal of Allied Health Sciences and Practice, 2022

ATTITUDES TOWARD COVID-19 AND VACCINATIONS

6

16. Peretz SB, Regev N, Novick L, Nachshol M, Goffer E, Ben-David A, Asraf K, Doolman R, Levin EG, Yochay GR, Yinon
Y. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. Ultrasound in
Obstetrics Gynecology. 2021;58:450-456.
17. Pegu A, O’Connell SE, Schmidt SD, O’Dell S, Talana CA, Lai L, Albert J, Anderson E, Bennett H, Corbett KS, Flach B,
Jackson L, Leav B, Ledgerwood JE, Luke CJ, Makowski M, Nason MC, Roberts PC, Roederer M, Rebolledo PA,
Rostad CA, Rouphael NG, Shi W, Wang L, Widge AT, Yang ES, Beigel JH, Graham BS, Mascola JR, Suthar MS,
McDermott AB, Doria-Rose NA. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.
Science. 373:1372-1377.
18. Pilishivili T, Gierke R, Fleming-Dutra KE, Farrar JL, Mohr NM, Talan DA, Krishnadasan A, Harland KK, Smithline HA,
Hou PC, Lee LC, Lim SC, Moran GJ, Krebs E, Steele MT, Beiser DG, Faine B, Haran JP, Nandi U, Schrading WA,
Chinnock B, Henning DJ, Lovecchio F, Lee J, Barter D, Brackney M, Fridkin SK, Marceaux-Galli K, Lim S, Phipps EC,
Dumyati G, Pierce R, Markus TM, Anderson DJ, Debes AK, Lin MY, Mayer J, Kwon JH, Safdar N, Fischer M, Singleton
R, Chea N, Magill SS, Verani JR, Schrag SJ. Effectiveness of mRNA COVID-19 vaccine among U.S. health care
personnel. The New England Journal of Medicine. 2021.
19. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Marc GP, Moreira ED, Zerbini C,
Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, French RW, Hammitt LL, Tureci O, Nell
H, Schaefer A, Unal S, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC. Safety and efficacy of
the BNT162b2 mRNA Covid-19 vaccine. The New England Journal of Medicine. 2020.
20. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, Frankland TB, Ogun OA, Zamparo JM, Gray
S, Valluri SR, Pan K, Angulo FJ, Jodar L, McLaughlin JM. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to
6 months in a large integrated health system in the USA: A retrospective cohort study. Lancet. 2021;398:1407-1416.
21. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, Hernan MA, Lipsitch M, Phil D, Kohane I, Netzer
D, Reis BY, Balicer RD. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. The New England
Journal of Medicine. 2021;381(12):1078-1090.
22. Shenai MB, Rahme R, Noorchasm H. Equivalency of protection from natural immunity in COVID-19 recovered versus
fully vaccinated persons: A systematic review and pooled analysis. Cureus. 2021;13(10).
23. Kwok KO, Li KK, Wei WI, Tang A, Wong SY, Lee SS. Influenza vaccine uptake, COVID-19 vaccination intention and
vaccine hesitancy among nurses: A survey. International Journal of Nursing Studies. 2021;114(1).
24. Manning ML, Gerolamo AM, Marino MA, Hanson-Zalot ME, Pogorzelska-Maziarz M. COVID-19 vaccination readiness
among nurse faculty and student nurses. Nursing Outlook. 2021;69:565-573.
https://doi.org/10.1016/j.outlook.2021.01.019
25. Cage SA, Warner BJ, Mesman D, Gallegos DM, Warner LK, Goza JP. Attitudes toward and usage of face masks or
face coverings among certified athletic trainers during the COVID-19 pandemic. Research & Investigations in Sports
Medicine. 2020;6(5):565-569.
26. Cage SA, Warner BJ, Ballard B, Gallegos DM, Goza JP, Warner LK. Attitudes toward COVID-19 vaccination among
athletic trainers in early 2021. Research & Investigations in Sports Medicine. 2021;8(1):693-696.
27. Sim MR. The COVID-19 pandemic: Major risks to healthcare and other workers on the front line. Occupational and
Environmental Medicine. 2020;77(5):281-282.
28. Cage SA, Warner BJ, Mesman D, Warner LK, Gallegos DM, Trail LE, Tuell C, Goza JP. Attitudes and Moods Among
Athletic Trainers Following Suspension of 2020 Athletic Season Due to COVID-19. Research & Investigations in Sports
Medicine. 2020;6(3):523-527.
29. Shreffler J, Petrey J, Huecker M. The impact of COVID-19 on healthcare worker wellness: A scoping review. Western
Journal of Emergency Medicine. 2020;21(5):1059-1066.
30. Mosheva M, Gross R, Hertz-Palmor N, Hasson-Ohayon I, Kaplan R, Cleper R, Kreiss Y, Gothelf D, Pessach IM. The
association between witnessing patient death and mental health outcomes in frontline COVID-19 healthcare workers.
Depress Anxiety. 2021;38:468-479.
31. Kundi M, Obermeier P, Helfert S, Oubari H, Fitzinger S, Yun JA, Brix M, Rath B. The impact of the patient-physician
relationship on parental vaccine safety perceptions. Current Drug Safety. 2015;10:16-22.
32. Guarinoni MG, Dignani L. Effectiveness of the school nurse role in increasing the vaccine coverage rate: A narrative
review. Ann IG. 2021;33(1):55-66.
33. Gilkey MB, Malo TL, Shah PD, Hall ME, Brewer NT. Quality of physician communication about human papillomavirus
vaccine: Findings from a national survey. Cancer Epidemiol Biomarkers Prev. 2015;24(11):1673-1679.
34. Burke K, Schwartz S, Breda K. Don’t hesitate, vaccinate! An influenza vaccine education program. Nursing Forum.
2019;54(4):553-556. https://doi-org.libproxy.uncg.edu/10.1111/nuf.12369
35. Navin MC, Wasserman JA, Ahmad M, Bies S. Vaccine educations, reasons for refusal, and vaccine education.
American Journal of Preventive Medicine. 2019;56(3):359-367. https://doi.org/10.1016/j.amepre.2018.10.024
© The Internet Journal of Allied Health Sciences and Practice, 2022

ATTITUDES TOWARD COVID-19 AND VACCINATIONS

7

36. Zarci S, Arrighi JF, Ongaro G, Calzascia T, Haller O, Frossard C, Piguet V, Walker PR, Hauser C. Efficient induction of
C8 T-associated immune protection by vaccination with mRNA transfected dendritic cells. Journal of Investigative
Dermatology. 2003;121(4):745-750. doi: 10.1046/j.1523-1757.2003.12492.
37. Carralot JP, Probst J, Hoerr I, Scheel B, Teufel R, Jung G, Rammensee HGG, Pascolo S. Polarization of immunity
induced by direct injection of naked sequence stabilized mRNA vaccines. Cellular and Molecular Life Sciences.
2004;61(18):2418-2424. doi: 10.1007/s00018-004-4255-0
38. Kyte JA, Kvalheim G, Lislerud K, Straten PR, Dueland S, Aamdal S, Gaudernack G. T cell responses in melanoma
patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunology, Immunotherapy.
2007;56:659-675. doi: 10.1007/s00262-006-0222-y
39. Roesler E, Weiss R, Weinberger EE, Fruehwirth A, Stoecklinger A, Mostbock S, Ferreira F, Thahamer J. Immunize
and disappear – Safety-optimized mRNA vaccination with a panel of 29 allergens. Journal of Allergy and Clinical
Immunology. 2009;124(5):1070-1077. doi: 10.1016/j.jaci.2009.06.036
40. Hosoi A, Takeda Y, Sakuta K, Ueha S, Kurachi M, Kimura K, Maekawa R, Kakimi K. Dendritic cell vaccine with mRNA
targeted to the proteasome by polyupiquitination. Biochemical and Biophysical Research Communications.
2008;371:242-246. doi:10.1016/j.bbrc.2008.04.034
41. Wong G, Gao GF. An mRNA-based vaccine strategy against Zika. Cell Research. 2017;27:1077-1078. doi:
10.1038/cr.2017.53
42. Wong SS, Webby RJ. An mRNA vaccine for influenza. Nature Biotechnology. 2012;30(12):1202-1204.
doi:10.1038/nbt.2349
43. Son SM, Hong HN. Changes in the job commitment and social interaction anxiety among occupational therapists
working in long term care hospital through the COVID-19 vaccination. Annals of the Romanian Society for Cell Biology.
2021;25(5):5691-5701. ISSN: 1583-6258.
44. Usher R, Sapleton T. Occupational therapy and decision-making capacity assessment: A survey of practice in Ireland.
Australian Occupational Therapy Journal. 2020;67:110-120.
45. Stein Duker LI, Sleight AG. Occupational therapy practice in oncology care: Results from a survey. Nursing & Health
Sciences. 2019;21:164-170.

© The Internet Journal of Allied Health Sciences and Practice, 2022

ATTITUDES TOWARD COVID-19 AND VACCINATIONS

8

APPENDIX: SURVEY FORM

Athletic Trainers Attitudes Toward COVID-19
and COVID-19 Vaccines
Q1 You are being invited to participate in a study about attitudes surrounding COVID-19 and COVID-19 Vaccines among athletic
trainers by S. Andrew Cage. Your participation is completely voluntary, and if you begin participation and choose to not complete
it, you are free to not continue without any adverse consequences.
If you agree to be in this study, we will ask you to do the following things:
You agree to have your survey answers included in data analysis.
Your data will not be shared with any other parties outside of the investigators. No identifying information will be included so that
your confidentiality will be protected. This means that your survey responses will be entirely anonymous.
We know of no known risks to this study, other than becoming a little tired of answering the questions, or you may even become
a little stressed or distressed when answering some of the questions. You are free to take a break and return to the survey to
finish it, or, you can discontinue participation without any problems.
If I need to ask questions about this study, I can contact the principle researcher, S. Andrew Cage at scage@uttyler.edu, or 903565-5545.
I have read and understood what has been explained to me. If I choose to participate in this study, I will click “I agree to
participate ” in the box below and proceed to the survey. If I choose to not participate, I will click “I do not agree to participate” in
the box below.

o
o

I agree to participate (1)
I do not agree to participate (2)

Q2 Please enter your age to the nearest year.
________________________________________________________________
Q3 Please enter your years of credentialed experience to the nearest year.
________________________________________________________________
Q4 What is your gender?
________________________________________________________________
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Q5 What is your race? (Please select all that apply)

▢
▢
▢
▢
▢
▢
▢

White (1)
Black or African American (2)
American Indian or Alaska Native (3)
Asian (4)
Native Hawaiian or Pacific Islander (5)
Hispanic, Latino(a), or Spanish (6)
Other (please describe) (7) ________________________________________________

Q6 What is the highest level of education you have completed?

o
o
o
o
o
o

Professional Bachelor's Degree (1)
Professional Master's Degree (MAT, MSAT) (2)
Post-Professional Master's Degree in Athletic Training (3)
Post-Professional Master's Degree not in Athletic Training (4)
Clinical Doctorate (DAT, DPT) (5)
Academic Doctorate (PhD, EdD) (6)

Q7 What is your current practice setting?

o
o
o
o

Secondary School (1)
College/University - Clinical (2)
College/University - Academic (3)
College/University - Split Appointment (4)
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o
o
o
o

Clinic/Hospital (5)
Professional Sports (6)
Emerging Settings (Military, Industrial, Performance Arts, etc.) (7)
Other (Please Describe) (8) ________________________________________________

Q8 The following questions are intended to describe your experiences with COVID-19. Please answer them to the best
of your abilities.
Q9 Have you been diagnosed with COVID-19 at any point in the past 2 years?

o
o

Yes (1)
No (2)

Q10 Have you received a COVID-19 vaccination?

o
o
o
o
o

Yes, Pfizer (1)
Yes, Moderna (2)
Yes, Johnson & Johnson (3)
Yes, Other (Please describe) (4) ________________________________________________
No (5)
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Q11 To what extent do you agree with this statement? I am confident in the level of authorization that has been awarded to
COVID-19 vaccines in the United States.

o
o
o
o
o
o

Strongly Agree (1)
Agree (2)
Somewhat Agree (3)
Somewhat Disagree (4)
Disagree (5)
Strongly Disagree (6)

Q12 To what extent do you agree with this statement? I am more confident in the Pfizer vaccine now that it has received full FDA
approval for individuals over the age of 16.

o
o
o
o
o
o

Strongly Agree (1)
Agree (2)
Somewhat Agree (3)
Somewhat Disagree (4)
Disagree (5)
Strongly Disagree (6)

Q13 If you have not received a COVID-19 vaccine, please share why you have not done so. If you have, please write "I have
received the vaccine".
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
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Q14 To what extent do you agree with the following question? In terms of general severity of symptoms, COVID-19 is just like
the seasonal influenza disease.

o
o
o
o
o
o

Strongly agree (1)
Agree (2)
Somewhat Agree (3)
Somewhat Disagree (4)
Disagree (5)
Strongly Disagree (6)

Q15 To what extent do you agree with the following question? In terms of general severity of symptoms, COVID-19 is worse than
the seasonal influenza disease.

o
o
o
o
o
o

Strongly Agree (1)
Agree (2)
Somewhat Agree (3)
Somewhat Disagree (4)
Disagree (5)
Strongly Disagree (6)
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Q16 To what extent do you agree with the following question? In terms of contagiousness, COVID-19 is just like the seasonal
influenza disease.

o
o
o
o
o
o

Strongly Agree (1)
Agree (2)
Somewhat Agree (3)
Somewhat Disagree (4)
Disagree (5)
Strongly Disagree (6)

Q17 To what extent do you agree with the following question? In terms of contagiousness, COVID-19 is worse than the seasonal
influenza disease.

o
o
o
o
o
o

Strongly Agree (1)
Agree (2)
Somewhat Agree (3)
Somewhat Disagree (4)
Disagree (5)
Strongly Disagree (6)

Q18 Have you had someone close to you hospitalized with COVID-19?

o
o

Yes (1)
No (2)

Q19 Has someone close to you passed away from COVID-19?

o
o

Yes (1)
No (2)
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Q20 To what extent do you agree with this statement? I am concerned about COVID-19 from the standpoint of my patient
population's health.

o
o
o
o
o
o

Strongly Agree (1)
Agree (2)
Somewhat Agree (3)
Somewhat Disagree (4)
Disagree (5)
Strongly Disagree (6)

Q21 To what extent do you agree with this statement? I am concerned about COVID-19 from the standpoint of disrupting the
competition season for my patient population.

o
o
o
o
o
o

Strongly Agree (1)
Agree (2)
Somewhat Agree (3)
Somewhat Disagree (4)
Disagree (5)
Strongly Disagree (6)
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Q22 To what extent do you agree with this statement? I am more concerned about COVID-19 affecting the health of my patient
population rather than affecting their competition season.

o
o
o
o
o
o

Strongly Agree (1)
Agree (2)
Somewhat Agree (3)
Somewhat Disagree (4)
Disagree (5)
Strongly Disagree (6)
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